Navigation Links
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
Date:6/26/2010

pan class="xn-money">$174 billion per year in direct and indirect medical expenses.(iv)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(v) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(vi) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vii,viii)

About BYETTA® (exenatide) injection

BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight-loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. See important safety information below.  Additional information about BYETTA is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Depth charge: Using atomic force microscopy to study subsurface structures
2. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
3. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
4. Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis
5. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
6. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
7. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
8. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
9. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
10. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
11. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... on December 10, 2007, SPACE COAST, Fla., ... its Third Annual Colloquium on the Law of,Transbeman ... will,be held December 10, 2007 along Florida,s Space ... flesh and computerized,substrate., The colloquia are open ...
... quarters of our universe is made up of some weird, ... dark energy. This month in Physics World, Eric ... at Berkeley, reveal how little we know about dark energy ... we can expect in the coming decade from a series ...
... Inc. (Nasdaq: SGMO ) announced today that Edward ... the progress of,Sangamo,s ZFP Therapeutic development programs and an ... on Tuesday, December 4, 2007 at,the BMO Capital Markets ... The presentation will be webcast live and may be ...
Cached Biology Technology:International Human Rights Day Recognized by Terasem Movement, Inc.'s Third Annual Colloquium on the Law of Transbeman Persons 2Dark energy -- 10 years on 2Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference 2
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... DALLAS , July 3, 2014 ... Sensors Market by Type (Swipe And Area), Material (Optical ... Defense, Healthcare, Commercial Security and Banking & Finance), and ... 2020", published by MarketsandMarkets, the global Fingerprint Sensors Market ... at a high CAGR of 16.8% from 2014 to ...
(Date:7/10/2014)... Sweden , July 7, 2014 ... its first major design win (DW). A Chinese Top 5 ... the planned start of mass production in October 2014.   ... a Chinese Top 5 smartphone OEM, which has a planned ... and a target sales volume for this phone of 3 ...
Breaking Biology News(10 mins):Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... In our not-so-distant evolutionary past, stress often meant ... so part of our body,s stress response is ... Medicine Partnership Unit (MMPU), a collaboration between the ... and the University of Heidelberg Medical Centre, have ...
... in the long-standing arms race between the flowering plant ... Duke University researchers have found that the little mustard ... prepare for the greatest onslaught of infectious spores released by ... time of day it is and change their activities accordingly, ...
... PORTLAND, Ore. -- The pediatric cardiac team at Oregon ... first in the region and one of a handful ... without open-heart surgery. To date, four patients have ... Adult Congenital Cardiac Catheterization Lab. All reported immediate improvement ...
Cached Biology News:Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3Plant's immune defense revs up for the morning attack 2Plant's immune defense revs up for the morning attack 3OHSU fixes complex heart problems without open-heart surgery 2
...
...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
Biology Products: